Background: Severe neonatal hyperbilirubinemia, with consequent encephalopathy, remains a common cause of morbidity and death in many regions of the world. Poor access to clinical laboratory resources and screening programs to measure plasma bilirubin levels is a major contributor to delayed treatment in developing countries, and the cost of existing point-of-care screening instruments precludes their dissemination. Objectives: We are evaluating the accuracy of a low-cost, minimally invasive point-of-care system (Bilistick) requiring a 25-µl blood sample that could be used in low-resource environments to evaluate patients with neonatal jaundice. Methods: We compared plasma bilirubin levels in divided blood samples by clinical laboratories and by Bilistick at two medical centers serving term and near-term newborns from ethnically different populations. Results: 118 neonates with bilirubin levels ranging from 24.8 to 501.0 µmol/l were analyzed. The mean bilirubin concentration (±SD) was 215.6 ± 85.5 µmol/l for Bilistick and 226.1 ± 86.4 µmol/l by laboratory determination. Pearson’s correlation coefficient between all paired results was 0.961, and the Bland-Altman analysis showed a mean difference of 10.3 µmol/l with a 95% interval of agreement of –38.0 to 58.7 µmol/l. Conclusion: Bilistick is a minimally invasive method for measuring total bilirubin concentration over a wide range of values and should provide an affordable and accurate system for pre-discharge and follow-up screening of jaundiced infants, particularly in low-resource environments.

Keywords:
Bilistick, Bilirubin, Point of care, Neonatal jaundice
1.
Ahlfors CE, Wennberg RP: Bilirubin-albumin binding and neonatal jaundice. Semin Perinatol 2004;28:334–339.
2.
Ostrow JD, Pascolo L, Shapiro SM, Tiribelli C: New concepts in bilirubin encephalopathy. Eur J Clin Invest 2003;33:988–997.
3.
Ali R, Ahmed S, Qadir M, Ahmad K: Icterus neonatorum in near-term and term infants: an overview. Sultan Qaboos Univ Med J 2012;12:153–160.
4.
Watchko JF: Kernicterus and the molecular mechanisms of bilirubin-induced CNS injury in newborns. Neuromolecular Med 2006;8:513–529.
5.
Hameed NN, Na’ Ma AM, Vilms R, Bhutani VK: Severe neonatal hyperbilirubinemia and adverse short-term consequences in Baghdad, Iraq. Neonatology 2011;100:57–63.
6.
Slusher TM, Vreman HJ, McLaren DW, Lewison LJ, Brown AK, Stevenson DK: Glucose-6-phosphate dehydrogenase deficiency and carboxyhemoglobin concentrations associated with bilirubin-related morbidity and death in Nigerian infants. J Pediatr 1995;126:102–108.
7.
Ogunlesi TA, Ogunfowora OB: Predictors of acute bilirubin encephalopathy among Nigerian term babies with moderate-to-severe hyperbilirubinaemia. J Trop Pediatr 2011;57:80–86.
8.
Brown AK, Damus K, Kim MH, et al: Factors relating to readmission of term and near-term neonates in the first two weeks of life. Early Discharge Survey Group of the Health Professional Advisory Board of the Greater New York Chapter of the March of Dimes. J Perinat Med 1999;27:263–275.
9.
Grohmann K, Roser M, Rolinski B, et al: Bilirubin measurement for neonates: comparison of nine frequently used methods. Pediatrics 2006;117:1174–1183.
10.
Slusher TM, Zipursky A, Bhutani VK: A global need for affordable neonatal jaundice technologies. Semin Perinatol 2011;35:185–191.
11.
Kaplan M, Bromiker R, Hammerman C: Severe neonatal hyperbilirubinemia and kernicterus: are these still problems in the third millennium? Neonatology 2011;100:354–362.
12.
Iskander I, Gamaleldin R, Kabbani M: Root causes for late presentation of severe neonatal hyperbilirubinaemia in Egypt. Eastern Mediterr Health J 2012;18:882–887.
13.
Ebbesen F, Vandborg PK, Trydal T: Comparison of the transcutaneous bilirubinometers BiliCheck and Minolta JM-103 in preterm neonates. Acta Paediatr 2012;101:1128–1133.
14.
Bertini G, Pratesi S, Cosenza E, Dani C: Transcutaneous bilirubin measurement: evaluation of Bilitest. Neonatology 2008;93:101–105.
15.
Campbell DM, Danayan KC, McGovern V, Cheema S, Stade B, Sgro M: Transcutaneous bilirubin measurement at the time of hospital discharge in a multiethnic newborn population. Paediatr Child Health 2011;16:141–145.
16.
Engle WD, Jackson GL, Sendelbach D, Manning D, Frawley WH: Assessment of a transcutaneous device in the evaluation of neonatal hyperbilirubinemia in a primarily Hispanic population. Pediatrics 2002;110:61–67.
17.
Engle WD, Jackson GL, Stehel EK, Sendelbach DM, Manning MD: Evaluation of a transcutaneous jaundice meter following hospital discharge in term and near-term neonates. J Perinatol 2005;25:486–490.
18.
Karen T, Bucher HU, Fauchere JC: Comparison of a new transcutaneous bilirubinometer (Bilimed) with serum bilirubin measurements in preterm and full-term infants. BMC Pediatr 2009;9:70.
19.
Raimondi F, Lama S, Landolfo F, et al: Measuring transcutaneous bilirubin: a comparative analysis of three devices on a multiracial population. BMC Pediatr 2012;12:70.
20.
Romagnoli C, Zecca E, Catenazzi P, Barone G, Zuppa AA: Transcutaneous bilirubin measurement: comparison of Respironics BiliCheck and JM-103 in a normal newborn population. Clin Biochem 2012;45:659–662.
21.
Maisels MJ, Engle WD, Wainer S, Jackson GL, McManus S, Artinian F: Transcutaneous bilirubin levels in an outpatient and office population. J Perinatol 2011;31:621–624.
22.
Mielsch C, Zimmermann A, Wagner D, Matthes B, Schlebusch H, Luppa PB: Point-of-care determination of neonatal bilirubin with the blood gas analyzer RapidLab 1265. Clin Chem Lab Med 2010;48:1455–1461.
23.
Barko HA, Jackson GL, Engle WD: Evaluation of a point-of-care direct spectrophotometric method for measurement of total serum bilirubin in term and near-term neonates. J Perinatol 2006;26:100–105.
24.
McKenzie J, Palmer B: Cost comparison of heel stick procedures and transcutaneous sample methods for bilirubin evaluation. Neonatal Intensive Care 2010;23:39–42.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.